Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Abstract Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. These antibodies de...

Full description

Bibliographic Details

Published in:	Molecular Cancer
Main Authors:	Linyan Cheng, Lujun Chen, Yuan Shi, Weiying Gu, Weidong Ding, Xiao Zheng, Yan Liu, Jingting Jiang, Zhuojun Zheng
Format:	Article
Language:	English
Published:	BMC 2024-04-01
Subjects:	Bispecific antibodies Immune checkpoint inhibitors Cancer Efficacy Safety
Online Access:	https://doi.org/10.1186/s12943-024-01956-6